Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
16th Clinical Trials on Alzheimer's Disease (CTAD) Conference
October 24 - 27, 2023; Boston, Massachusetts
October 24 - 27, 2023Boston, Massachusetts
CTAD 2023No Influence of APOE Status on Donanemab Efficacy New data from TRAILBLAZER-ALZ 2 show robust amyloid clearance with donanemab in APOE4 carriers and noncarriers, mitigating the risk of disease progression and dependency.
Medscape Medical News, October 27, 2023
CTAD 2023Novel Tau Blood Biomarker Shows PromisePlasma MTBR-tau243 reflects changes in tau pathology and can be used to stage AD tauopathy and to determine if cognitive symptoms are likely due to AD pathology.
Medscape Medical News, October 26, 2023
CTAD 2023Promising Phase 2 Results for Novel Oral Alzheimer's DrugAn investigational dual PPAR agonist modifies Alzheimer's pathology and shows cognitive benefit in adults with mild-to-moderate disease and high plasma pTau-217 ratio, early data show.
'Modest' Benefit for Lecanemab in AD, Adverse Events CommonFull presentation of the phase 3 CLARITY AD trial results shows mixed findings for the experimental drug Lecanemab, and reported
deaths have raised questions about the drug's safety.
Medscape Medical News, Nov 29, 2022
Antipsychotic Shows Benefit for Alzheimer's AgitationResearchers reported that a phase 3 study showed statistically significant improvement in patients with agitation related
to Alzheimer's who took the atypical antipsychotic brexpiprazole.
Medscape Medical News, Dec 05, 2022
Odd Twist in Phase 3 Alzheimer's Trial for Novel Tau InhibitorAlthough the novel tau aggregation inhibitor hydromethylthionine mesylate did not reach its coprimary endpoints, investigators
insist there's more to the story - especially with the control agent used.
